Sign in
Not yet taking people in United StatesPhase 2

Allopregnanolone in Chronic Complex Traumatic Brain Injury

Key facts

Who runs it
VA Office of Research and Development
Where
Durham, United StatesSee the site
Trial code
Status
Not yet recruiting
Phase
Phase 2
People taking part
132 people, planned
Starts
1 Dec 2026
Expected to end
1 Jun 2027
Type of study
Interventional, 3 groups
Treatments tested
  • Placebo
  • Allopregnanolone
Record updated
19 October 2026

Who can take part

Age
21 years to 62 years
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 20 criteriaShow less

Who can take part

  • Any ethnic group
  • History of mild traumatic brain injury (TBI) since 2001 and service in the U.S. Military since 9/11/01 (OEF/OIF/OND era)
  • The investigators will adhere to the operational definition of mild TBI suggested by the World Health Organization Task Force, with the exception of seizure and Glasgow Coma Scale score criteria (not available for these participants) with 1 or more of the following:; confusion or disorientation; loss of consciousness for 30 minutes or less; post-traumatic amnesia for less than 24 hours; and/or other transient neurological abnormalities such as focal signs, and intracranial lesion not requiring surgery
  • Ability to participate fully in the informed consent process
  • Hamilton Depression Rating Scale (HDRS) score 14 (HAM-D range for moderate depression=14-18)
  • Participants will meet Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5 criteria for major depressive disorder (by SCID); The presence of psychotic features will be exclusionary; Single episodes or recurrent episodes will be permissible for study entry (the investigators will examine treatment responses in those who have had single depressive episodes versus those who have had multiple depressive episodes in exploratory sensitivity analyses
  • BPI (Brief Pain Inventory, Short Form) 'current' pain intensity rating item score 4 (scale of 0-10); Pain must be musculoskeletal in nature
  • No anticipated need to alter psychiatric medications for 14-day duration of study involvement
  • No changes in psychotropic or behavioral interventions during the study or in the 2 weeks prior to study enrollment
  • Concomitant medications for co-occurring medical conditions are permissible for stable medical conditions that are reasonably well-controlled; for example, hypertension medications, statins, and oral hypoglycemic medications would generally be permissible if they appear to be effectively treating the underlying condition

Who cannot take part

  • Medications that could potentially confound study outcomes (for example, prednisone) are exclusionary
  • Current DSM-5 diagnosis of bipolar disorder, schizophrenia or other psychotic disorder, or cognitive disorder due to a general medical condition other than traumatic brain injury (TBI)
  • Known allergy to study medication
  • Substance use disorder (DSM-5), other than nicotine use disorder
  • A serious medical illness, defined as an illness that requires hospitalization for additional care at the time of screening or one that has required hospitalization in the last month; Any co-occurring medical illness should have a history of stable outpatient management
  • Report of a history of seizures, a history of stroke, a history of prostate cancer (or any other cancer other than non-melanoma skin cancer), a history of myocardial infarction, the presence of congestive heart failure, or any other serious health condition that would likely preclude safe study participation in the medical opinion of the principal investigator (PI) or in consultation with the participant's Primary Care Provider (PCP)/other health care provider
  • Participants with current suicidal or homicidal ideation necessitating clinical intervention or representing an imminent concern
  • Female participants who are pregnant or breast-feeding
  • Benzodiazepine, barbiturate, or opioid use within the last 2 weeks is exclusionary
  • Use of oral contraceptives, a hormone-releasing IUD, or other hormonal supplementation such as estrogen or progesterone, as there is a theoretical risk that a metabolite such as ALLO could potentially impact efficacy of oral contraceptives or estrogen replacement

The main criteria, as questions

These questions come from the eligibility criteria published for this trial. They help you read the criteria and prepare for a talk with your doctor or the study team. We do not tell you a result. Only the study team can say whether you can take part.

  • Are you between 21 and 62 years old?

Where in United States

  • Durham VA Medical Center, Durham, NCDurham, United StatesContact: Christine E Marx, MD MANot yet recruiting

About the trial

What the trial wants to find out

This study will determine if allopregnanolone (ALLO) improves depression and pain symptoms in patients who have a history of mild traumatic brain injury (TBI) [primary endpoints]. The investigators will also determine if ALLO improves functional outcome [secondary endpoint]. Participants in this study will receive an intravenous infusion of either ALLO or placebo. Behavioral assessments will be conducted during the infusion and at several time points post-infusion.

The 3 groups in the trial

  • PlaceboTreatment being tested

    ALLO 0 nanomolar (nM) (placebo: loading dose, 4-hour infusion, taper)

  • ALLO 50 nanomolar (nM)Treatment being tested

    ALLO 50 nanomolar (nM) (lower dose ALLO: loading dose, 4 hour infusion, taper)

    Treatment: Allopregnanolone

  • ALLO 150 nanomolar (nM)Treatment being tested

    ALLO 150 nanomolar (nM) (higher dose ALLO: loading dose, 4 hour infusion, taper)

    Treatment: Allopregnanolone

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Novel Regenerative Therapeutic in Chronic Complex TBI
Criteria questions
Built from NCT04003285, who can take part
Record updated
19 October 2026